Related Experiment Video
Updated: Feb 6, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
Aaron Galaznik1,1, Rachel Huelin2,2, Michael Stokes3,3
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USA.
Abstract:
To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012-May 2016. Among 33 included articles, therapies included stem cell transplant (SCT) and chemotherapy, including experimental regimens. The highest overall survival rates were observed for SCT, long considered an optimal strategy following initial relapse. Prognoses were inferior among DLBCL patients receiving rituximab-based regimens rather than SCT, particularly among studies that exclusively focused on those ineligible for SCT due to age or co-morbidity. A lack of viable treatment options for DLBCL/FL patients ineligible for SCT after relapse remains a significant gap in care.
Related Concept Videos
Diffusion
Diffusion
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Systematic Sampling Method
Systematic sampling is one of the simplest methods...

